Understand the source comparison
KPV Combined with Other Peptides: Comparison Table
KPV + BPC-157 NF-κB inhibition + VEGF upregulation and FAK-paxillin activation KPV 500mcg AM, BPC-157 250–500mcg PM, both subcutaneous daily Inflammatory bowel disease, gastric ulcers, joint inflammation, post-surgical healing None documented; pathways operate
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- KPV + BPC-157
- NF-κB inhibition + VEGF upregulation and FAK-paxillin activation
- KPV 500mcg AM, BPC-157 250–500mcg PM, both subcutaneous daily
- Inflammatory bowel disease, gastric ulcers, joint inflammation, post-surgical healing
- None documented; pathways operate independently
- Strongest evidence base for synergistic anti-inflammatory and healing effects. Gold standard combination
- KPV + TB-500
- NF-κB inhibition + actin polymerization and endothelial migration
- KPV 500mcg daily, TB-500 2mg twice weekly (PM, separate days), both subcutaneous
- Tendon/ligament injuries, muscle tears, chronic joint inflammation
- None documented; TB-500's long half-life requires timing separation
- Highly effective for connective tissue repair. Slower onset but sustained benefit over 4–8 weeks
- KPV + Thymosin Alpha-1
- NF-κB inhibition + T-cell differentiation and cytokine modulation
- KPV 500mcg twice weekly, Thymosin Alpha-1 1.6mg twice weekly (non-overlapping days), both subcutaneous
- Autoimmune flares, chronic infections, immune-modulated skin conditions
- Minimal; both suppress inflammation but via different pathways
- Best for immune-driven inflammatory conditions. Less data than BPC-157 combinations but mechanistically sound
- KPV + Growth Hormone Secretagogues (e.g., Ipamorelin)
- NF-κB inhibition + GH/IGF-1 axis activation
- KPV 500mcg AM, Ipamorelin 200–300mcg PM, both subcutaneous daily
- Wound healing, metabolic recovery, age-related inflammation
- Theoretical only. No published interaction studies
- Limited evidence; GH secretagogues promote anabolism while KPV reduces catabolism. May be synergistic but requires caution
- KPV + Melanotan II
- Redundant. Both derived from α-MSH
- Not recommended
- N/A
- High. Receptor competition likely
- Poor combination; Melanotan II activates melanocortin receptors that KPV may also interact with. Overlap negates benefits
- KPV + Other NF-κB Inhibitors (e.g., Curcumin peptides)
- Redundant. Same pathway
- Moderate. No added benefit, potential for excessive immune suppression
- Stacking two NF-κB inhibitors provides no additional anti-inflammatory benefit and increases risk of over-suppressing immune response